<DOC>
	<DOCNO>NCT00526253</DOCNO>
	<brief_summary>This study inject person 's stem cell heart muscle tissue person one heart attack . The purpose study whether stem cell improve patient 's heart performance .</brief_summary>
	<brief_title>To Assess Safety Efficacy Myoblast Implantation Into Myocardium Post Myocardial Infarction</brief_title>
	<detailed_description>Autologous myoblasts harvest patient 's skeletal muscle tissue . The myoblasts isolate expanded culture close system . When sufficient number cell estimate take culture , package suspension send patient 's interventionalist . The interventionalist us injection catheter via femoral artery inject myoblasts directly myocardium .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Eligible patient must meet ALL follow inclusion criterion screening/enrollment visit # 1 prior randomize study . Screening/enrollment visit # 1 defined start date ICF sign patient : 1 . Chronic CHF , New York Heart Association ( NYHA ) Class IIIV ; 2 . Stable optimal medical management great equal 60 day follow : 1. systolic diastolic hypertension control accordance contemporary guideline ; 2. patient stabilize maximum tolerate dose beta blocker ; 3. patient stabilize maximum tolerate dose angiotensin concert enzyme ( ACE ) inhibitor ; 4. patient intolerant ACE inhibitor stabilize angiotensin receptor blocker ( ARB ) ; 5. fluid control diuretic salt restrict diet ; 6. patient sever symptom heart failure ( Class IIIIV ) lack contraindication aldosterone antagonism ACE inhibitor ARBs consider therapy . 3 . Age 1880 ; 4 . Left ventricular ejection fraction ( LVEF ) screen less equal 35 percent multiple gaited acquisition scan ( MUGA ) ; 5 . Need feasibility revascularization rule previous coronary angiogram rule satisfaction investigator via previous conventional stress study complete within 1 year screening . The need feasibility revascularization reassess screen use dobutamine stress echocardiography ( DSE ) ; 6 . Defined region mycardial dysfunction relate previous MI involve anterior , later , posterior inferior wall include apical septum ( exclude basal septum ) assess large area akinesia leave ventricle ( use DSE screening ) ; 7 . Btype natriuretic peptide ( BNP ) NT proBNP upper limit normal . 1 . Nonpregnant woman postmenopausal , surgically sterile practice acceptable method contraception . A female patient child bear potential , positive serum urine pregnancy test screen visit # 1 . Females refuse exercise reliable form contraception ; 2 . Myocardial wall thickness &lt; 6 mm ( millimeter ) akinetic myocardial region inject ( use DSE screen ) 3 . Inability undergo surgical biopsy skeletal muscle culture myoblasts , include significant myopathy ; 4 . Patient require revascularization within six month ; 5 . Patients continuous intermittent intravenous drug therapy ; 6 . Not fit , fit within less 90 day prior screen visit # 1 , implantable cardioverter defibrillator ( ICD ) ; 7 . Sustained ventricular tachycardia ( VT ) , automatic implantable cardiodefibrillator ( AICD ) firing , ventricular fibrillation ( VF ) within 90 day prior screen visit # 1 ; 8 . Inability perform 6 minute walk test due physical limitation HF include : 1 . Severe peripheral vascular disease , include aortic aneurysm , lead limited claudication ; 2 . Severe pulmonary disease chronic obstructive pulmonary disease ( COPD ) limit exercise , dependence chronic oral steroid therapy previously require mechanical ventilation ; 3 . Stroke transient ischemic attack lead limitation low extremity occur within 180 day prior screen visit # 1 ; 9 . MI , unstable angina percutaneous coronary intervention ( PCI ) within 90 day prior screen ; 10. undergone CABG surgery within 150 day prior screen visit # 1 ; 11 . Active myocarditis , constrictive pericarditis , restrictive , hypertrophic congenital cardiomyopathy ; 12 . Hemodynamically significant severe primary valvular heart disease , unless correct properly functional prosthetic valve ; 13 . Prior aortic valve replacement ; 14 . Systolic blood pressure ( supine ) ≤90 mmHg ; 15 . Resting heart rate &gt; 100 bpm ; 16 . Severe uncontrolled HF include evidence severe fluid overload peripheral edema &gt; +2 rales ≥1/3 lung ' height , need intravenous therapy HF within 60 day screen visit # 1 hospitalization HF within 90 day screen visit # 1 ; 17 . Patient schedule receive cardiac resynchronization therapy ( CRT ) study ; 18 . Expected receive receive cardiac transplant , surgical remodeling procedure , leave ventricular assist device cardiomyoplasty ; 19 . Sixminute walk test ( 6MWT ) &gt; 400 meter Minnesota Living With Heart Failure ( MLWHF ) score &lt; 20 ; 20 . Hematocrit ( HCT ) concentration 30 % ( male ) 27 % ( female ) ; 21 . Serum creatinine great 2.5 mg/dL ( milligram per deciliter ) end stage renal disease ; 22 . Left ventricular mural thrombus ; 23 . Known sensitivity gentamicin sulfate ; severe adverse reaction nonionic radiocontrast agent ; 24 . Active infectious disease and/or know test positive human immunodeficiency virus ( HIV ) , human lymphotrophic virus ( HTLV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , cytomegalovirus ( CMV ) ; immunoglobulin M [ IgM ] , and/or syphilis . If panel include antibody HBV core antigen ( HBVcAg ) hepatitis B surface antigen ( HBVsAg ) , expert consult patient 's eligibility base patient 's infectious status ; 25 . Patients undergone enhance external pulsation ( EECP ) tratment within last 6 month ; 26 . Exposure previous experimental angiogenic therapy and/or myocardial laser therapy , therapy another investigational drug within 60 day screen visit # 1 enrollment concurrent study may confound result study ; 27 . Known drug alcohol dependence factor interfere study conduct interpretation result opinion investigator suitable participate ; 28 . Any illness CHF might reduce life expectancy le 1 year screen visit # 1 ; 29 . Recent initiation cardiac resynchronization therapy via placement biventricular pacemaker biventricular AICD within 180 day study enrollment ; 30 Unwilling and/or able give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Congestive Heart Failure</keyword>
	<keyword>CHF</keyword>
	<keyword>Heart Disease</keyword>
	<keyword>Heart Attack</keyword>
	<keyword>Stem Cell</keyword>
	<keyword>Myoblast</keyword>
	<keyword>Bioheart</keyword>
</DOC>